JAGUAR

Endologix Announces 150th Patient Enrolled in JAGUAR Randomized Controlled Trial

Retrieved on: 
Tuesday, May 23, 2023
Surgery, Hospitals, Clinical Trials, Cardiology, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Gauge, JAGUAR, Metaphilosophy, Aortic aneurysm, AAA, Patient, Randomized controlled trial, Vascular disease, EVAR, Medical imaging

This randomized controlled trial is evaluating Endologix’s ALTO Abdominal Stent Graft System, comparing its effectiveness to other commercially available endovascular aneurysm repair (EVAR) devices in the treatment of abdominal aortic aneurysms (AAA).

Key Points: 
  • This randomized controlled trial is evaluating Endologix’s ALTO Abdominal Stent Graft System, comparing its effectiveness to other commercially available endovascular aneurysm repair (EVAR) devices in the treatment of abdominal aortic aneurysms (AAA).
  • The JAGUAR (ObJective Analysis to GaUge EVAR Outcomes Through Randomization) Study is a prospective, randomized, multi-center study, designed to enroll 450 patients at up to 60 sites.
  • "This milestone for Endologix underlines our dedication to clinical research and patient care," stated Matt Thompson, President, and CEO of Endologix.
  • “The JAGUAR trial, our second randomized study aimed at assessing comparative endograft performance, follows in the footsteps of our successful LEOPARD study.

ELEVATE IDE Study highlights the Safety and Effectiveness of the ALTO® Abdominal Stent Graft System in One-year Results; Data to Be Presented at 2022 VEITHsymposium

Retrieved on: 
Thursday, October 20, 2022
Health, Surgery, Clinical Trials, Medical Devices, Sale, Technology, Anatomy, Patient, EVAR, Society for Vascular Surgery, ISSN, Multimedia, Mortality, CT, Vascular disease, MD, Department, Acquisition, JAGUAR, Renal artery, AAAS, CEO, Cleveland Clinic, ALTO, Journal, Randomized controlled trial, AAA, Forward-looking statement, Aortic aneurysm, Stent, FDA, IDE, Medical imaging, Pharmaceutical industry

The study reports the clinical outcomes of the ALTO Abdominal Stent Graft System and highlights the devices safety and effectiveness at one-year post-procedure.

Key Points: 
  • The study reports the clinical outcomes of the ALTO Abdominal Stent Graft System and highlights the devices safety and effectiveness at one-year post-procedure.
  • The study concluded that the Endologix ALTO stent graft is safe and effective in treating AAA with appropriate anatomy at one year.
  • Featuring a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation of innovative therapies for AAA patients.
  • Endologixs current commercial EVAR products include the AFX2 Endovascular AAA System and the ALTO Abdominal Stent Graft System.

Trimble and CLAAS Strategic Alliance Develops Next-Generation Precision Farming System for CLAAS Agriculture Equipment

Retrieved on: 
Wednesday, August 24, 2022
TRMB, Power Marketing Administration, Decision-making, Technology, Season, Safety, JAGUAR, Agriculture, NASDAQ, Solution, GNSS, Administration, Food, SAT, CLAAS, Farmer, GPS, Trimble Inc., Multimedia, Head Office, LEXION, Architecture, Kansas Department of Agriculture, Division of Water Resources, Transport, Satellite navigation device

SUNNYVALE, Calif., Aug. 24, 2022 /PRNewswire/ -- As part of a strategic alliance, Trimble (NASDAQ: TRMB) and CLAAS have developed a next-generation precision farming system for CLAAS tractors, combines and forage harvesters.

Key Points: 
  • SUNNYVALE, Calif., Aug. 24, 2022 /PRNewswire/ -- As part of a strategic alliance, Trimble (NASDAQ: TRMB) and CLAAS have developed a next-generation precision farming system for CLAAS tractors, combines and forage harvesters.
  • The precision farming system includes the new CLAAS CEMIS 1200 "smart" display, GPS PILOT steering system and the SAT 900 GNSS receiver.
  • "Working in tandem with CLAAS, we have jointly developed a next-generation precision farming system designed aroundone common user interfaceto provide CLAAS operators the best-in-class customer experience."
  • "As an experienced, innovative and global provider of precision agriculture solutions, Trimble was our first choice as a technology partner," saidDr.

Endologix Initiates Randomized Study of ALTO® Abdominal Stent Graft System

Retrieved on: 
Wednesday, September 29, 2021
Surgery, Medical Devices, Health, Clinical Trials, Cardiology, Technology, Gauge, Abdominal aortic aneurysm, Hospital, Sentara Norfolk General Hospital, III, Patient, MD, EVAS, EVAR, JAGUAR, Vascular disease, Freedom, ALTO, Occlusion, AAA, Time, Christian philosophy, Aortic aneurysm, Medical imaging, the ALTO Abdominal Stent Graft System, Endologix, Deerfield Management, THE ALTO ABDOMINAL STENT GRAFT SYSTEM, ENDOLOGIX, DEERFIELD MANAGEMENT

Endologix LLC , a leader in the treatment of vascular disease, today announced that the first patient has been enrolled in the companys JAGUAR study to compare outcomes for the companys ALTO Abdominal Stent Graft System to other commercially available endovascular aneurysm repair (EVAR) devices for the treatment of abdominal aortic aneurysm (AAA).

Key Points: 
  • Endologix LLC , a leader in the treatment of vascular disease, today announced that the first patient has been enrolled in the companys JAGUAR study to compare outcomes for the companys ALTO Abdominal Stent Graft System to other commercially available endovascular aneurysm repair (EVAR) devices for the treatment of abdominal aortic aneurysm (AAA).
  • The study is designed for at least 300 patients to be randomly allocated to the ALTO cohort and 150 to the comparator group.
  • Featuring a unique, patented, sealing technology, the ALTO Abdominal Stent Graft System is the latest generation of innovative therapies for AAA patients.
  • Endologixs current commercial EVAR products include the AFX2 device and the ALTO Abdominal Stent Graft System.